Valjuvant Corporation

Valjuvant Corporation, a minority-owned, small disadvantaged business based in Glenview, Illinois, operates exclusively as a subcontractor on federal vaccine adjuvant research and development projects, with all recent work subcontracted to the University of Chicago under awards from the Department of Health and Human Services' National Institute of Allergy and Infectious Diseases.

Valjuvant is an Asian-Pacific American-owned, self-certified small disadvantaged business organized as a for-profit corporate entity. The vendor's recent federal footprint consists entirely of subcontract work — no prime awards or independent contract vehicles — with three awards obligating $1.1 million combined across 2025. All three sub-awards flow through the University of Chicago as prime contractor on NIH-funded vaccine development programs. The work centers on the design and optimization of small-molecule immune-modulating compounds, specifically the lead candidate PME-564, for use as vaccine adjuvants in influenza and pandemic-preparedness contexts. Two of the three sub-awards (May 2025) focus on development of adjuvanted formulations for improved influenza vaccines, including quadrivalent flu vaccines and mRNA-based H5N1 vaccine platforms, with goals of reducing systemic inflammation, improving reactogenicity profiles, and accelerating safety and toxicity assessment. A third sub-award (May 2025) targets identification of novel small-molecule adjuvant candidates that enhance T-cell responses without excessive inflammatory burden, with similar focus on formulation compatibility with both current and next-generation vaccine platforms. The vendor's technical contribution appears to be in small-molecule compound chemistry and adjuvant formulation optimization rather than manufacturing or clinical delivery.

Customer concentration is absolute — all three awards derive from NIAID, representing 100% of Valjuvant's tracked federal footprint. NAICS coding splits across Computer Systems Design Services (2 awards) and Research and Development in Biotechnology (1 award), suggesting the source may misclassify the vaccine-chemistry work or the vendor performs dual-track technical roles. Activity is minimal and recent; no pipeline visibility or recompete exposure exists in the source beyond the three 2025 sub-awards.